

# Supporting Information

Kawane et al. 10.1073/pnas.1010603107

## SI Materials and Methods

**Mice.** The DNase II<sup>-/-</sup>IFN-IR<sup>-/-</sup> and DNase II<sup>flox/-</sup>Mx1-Cre<sup>T</sup> mice were described previously (1). To delete the DNase II gene, the 4- to 5-wk-old DNase II<sup>flox/-</sup>Mx1-Cre<sup>T</sup> mice were given three times i.p. injections of poly(I):poly(C) at 0.8 μg/g bodyweight at 1-d intervals, and are referred to as DNase II<sup>Δ/-</sup> mice. The induced deletion of the DNase II gene in the bone marrow or joint of the DNase II<sup>Δ/-</sup> mice was confirmed by real-time PCR. The *TLR9*<sup>-/-</sup> (2), *Rag2*<sup>-/-</sup> (3), *IL-18*<sup>-/-</sup> (4), and *IL-6*<sup>-/-</sup> (5) mice on a B6 background were provided by S. Akira (Osaka University, Osaka), Y. Shinkai (Kyoto University, Kyoto), K. Nakanishi and H. Tsutsui (Hyogo College of Medicine, Nishinomiya, Japan), and M. Kopf (Eidgenössische Technische Hochschule, Zurich), respectively. *TNFα*<sup>-/-</sup> (6) mice on a B6/129 mixed background were provided by K. Sekikawa (National Institute of Agrobiological Sciences, Tsukuba).

**Antibodies.** The following mAbs and reagents were used for staining in FACS: anti-CD3 (clone KT3), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD11c (clone HL3), CD69 (clone H1.2F3), B220 (clone RA3-6BC), Gr-1 (clone RB6-8C5), Mac1 (clone M1/70), CD45.1 (clone A20), CD45.2 (clone 104), TER119 (clone TER119), Fcγ receptor III/II (clone 2.4G2), streptavidin-APC, and streptavidin-Alexa 488. All Abs and reagents were from BD Pharmingen or Biolegend.

**Primers Used for Genotyping.** Primers used for the mouse genotypes were as follows:

DNase II: WT sense, 5'-CAGTGCCACAGAGGACCACT-3'  
mutant sense, 5'-GATTCGCAGCGCATCGCCTT-3'  
common antisense, 5'-GAGTCTTAGTCCTTTGCTCCG-3'.

IFN-IR: WT antisense, 5'-AAGATGTGCTGTTCCCTTCCT-  
CTGCTCTGA-3'  
mutant antisense, 5'-CCTGCGTGCAATCCATCTTG-3'  
common sense, 5'-ATTATTAAGAAAAGACGAGGCG-  
AAGTGG-3'.

TLR9: WT antisense, 5'-GAGTCTTAGTCCTTTGCTCCG-3'  
mutant antisense, 5'-ATCGCCTTCTATCGCCTTCTTGAC-  
GAG-3'  
common sense, 5'-GCAATGGAAAGGACTGTCCACTTT-  
GTG-3'.

Mx1-Cre: sense, 5'-GTGGGCACAGCAAGCTCAGG-3'  
antisense, 5'-TCCATGAGTGAACGAACCT-3'.

flox allele: sense, 5'-CGCACGTCTAAGAAACCATT-3'  
antisense, 5'-CAGTACTAGTGAACCTCTTC-3'.

Δ allele: sense, 5'-TAGGATACTCCAAAGGGAC-3'  
antisense, 5'-CAGTACTAGTGAACCTCTTC-3'.

Rag2: WT antisense, 5'-CTGATTTCAATCGTGTGTTGCC-3'  
mutant antisense, 5'-TGTGCCAGTCATAGCCGAA-3'  
common sense, 5'-GATTCCTGCTACCTCCACCT-3'.

TNFα: WT antisense, 5'-AGATGGAGAAGGGCAGTTAG-3'  
mutant antisense, 5'-GATTCGCAGCGCATCGCCTT-3'  
common sense, 5'-ATACCAGGGTTTGAGCTCAG-3'.

IL-6: WT antisense, 5'-TTCTCATTTCCACGATTTCCAG-3'  
mutant antisense, 5'-CCGGAGAACCCTGCGTGCAATCC-3'  
common sense, 5'-TTCCATCCAGTTGCCTTCTTGG-3'.

IL-18: WT sense, 5'-GGCATTGCGAGCTGCCAAATTCC-3'  
mutant sense, 5'-TGTGCCAGTCATAGCCGAA-3'  
common antisense, 5'-CTTGTGTGCTGGAACACG-3'.

**Real-Time PCR and ELISA for MMP-3.** The limbs, including the ankle joints, were separated from the skin and homogenized with a Polytron homogenizer in ISOGEN (Nippon Gene). Total RNA was prepared from the homogenates according to the manufacturer's instructions and purified using an RNeasy kit (Qiagen). RNA was reverse transcribed using SuperScript III (Invitrogen) with an oligo (dT) primer, and real-time PCR was carried out using a Light-Cycler480 (Roche Diagnostics). The specific mRNA was quantified at the upstroke of the exponential phase of PCR accumulation, compared with the standard curve, and normalized to the GAPDH or β-actin mRNA level. The serum MMP-3 level was determined with an ELISA kit from R&D Systems.

**Primers Used for Real-Time PCR.** Primers used for real-time PCR were as follows:

TNFα: sense primer, 5'-CACAGAAAGCATGATCCGCGA-  
CGT-3'  
antisense primer, 5'-CGGCAGAGAGGAGGTTGACTTT-  
CT-3'.

TGFβ: sense primer, 5'-GACCGCAACAACGCCATCTA-3'  
antisense primer, 5'-GGCGTATCAGTGGGGTTCAG-3'.

IL-1β: sense primer, 5'-CCAGCTTCAAATCTCACAGCAG-3'  
antisense, 5'-CTTCTTTGGGTATTGCTTGGGATC-3' or  
sense primer, 5'-CTGATGAGAGCATCCAGCTTCA-3'  
antisense, 5'-CTTCTTTGGGTATTGCTTGGGATC-3'.

IL-6: sense primer, 5'-TCCAGTTGCCTTCTTGGGAC-3'  
antisense primer, 5'-GTACTCCAGAAGACCAGAGG-3'.

IL-10: sense primer, 5'-TGGCCAGAAATCAAGGAGC-3'  
antisense primer, 5'-CAGCAGACTCAATACACACT-3'.

IL-17A: sense primer, 5'-AACACTGAGGCCAAGGACTT-3'  
antisense primer, 5'-ACCCACCAGCATCTTCTC G-3'.

DNase II: sense primer, 5'-GAGACGGTGATCAAGAAC-  
CAA-3'  
antisense primer, 5'-AATTTTGCCAGAAGTGGACCT-3'.

MMP-3: sense primer, 5'-ACTCTACCACTCAGCCAAGG-3'  
antisense primer, 5'-TCCAGAGAGTTAGACTTGGTGG-3'.

β-actin: sense primer, 5'-TGTGATGGTGGGAATGGGT-  
CAG-3'  
antisense primer, 5'-TTTGATGTCACGCACGATTTCC-3'.

GAPDH: sense primer, 5'-AACGACCCCTTCATTGAC-3'  
antisense primer, 5'-TCCACGACATACTCAGCAC-3'.

G-CSF: sense primer, 5'-GTTGTGTGCCACCTACAA GC-3'  
antisense primer, 5'-CCATCTGCTGCCAGATGGTGGT-3'.

CCL20: sense primer, 5'-AGAAGCAGCAAGCAACTACG-3'  
antisense primer, 5'-ACATCTTCTTACTCTTAGGC-3'.


**FACS Analysis.** Spleens were squashed between slide glasses and passed through a screen. To collect CD11c<sup>+</sup> cells, the debris trapped on the screen was dispersed in RPMI buffer, incubated with collagenase, and returned to the cell suspension. After a preincubation for 10 min at 4 °C with rat anti-Fcγ receptor III/II Ab, the cells were stained with Abs for 30 min at 4 °C in PBS containing 2% FCS, 0.05% NaN<sub>3</sub>, and 0.1 mg/mL propidium iodide and analyzed by FACS caliber (BD Biosciences) using Cell Quest software (Quest Software).

**Preparation of Synovial Cells.** Synovial cells were prepared essentially as described (7). In brief, joint capsules were harvested from knee joints of 5-wk-old to 8-wk-old C57/BL6 mice with razor blade,










**Fig. S5.** Mutual activation of TNF $\alpha$ , IL-1 $\beta$ , and IL-6 genes in synovial cells. Synovial cells in 96-microtiter plates were treated in triplicate in  $\alpha$ MEM with or without 20 ng/mL of mouse IL-1 $\beta$  (Peprotech) or 25 ng/mL of mouse IL-6 (BD Bioscience) plus 25 ng/mL of human IL-6R $\alpha$  (R&D Systems) for 24 h (A), with or without 15 ng/mL of mouse TNF $\alpha$  (Peprotech) or 25 ng/mL of mouse IL-6 plus 25 ng/mL of human IL-6R $\alpha$  for 23 h followed by stimulation with 6.5 mM ATP for 1 h (B), or with or without 15 ng/mL of mouse TNF $\alpha$  or 20 ng/mL of mouse IL-1 $\beta$  for 10 h (C). The levels of TNF $\alpha$  (A), IL-1 $\beta$  (B), and IL-6 (C) in the supernatants were determined by ELISA using kits from BD Bioscience (for TNF $\alpha$  and IL-6) and R&D Systems (for IL-1 $\beta$ ), and are plotted with SD. *P* values are shown.



**Fig. S6.** Expression of CCL-20 and G-CSF genes in the joints of DNase II-null mice. DNaseII $\Delta^{-/-}$ IL-6 $^{-/-}$  (A) and DNaseII $\Delta^{-/-}$ TNF $\alpha^{-/-}$  mice (B) were generated by treating with poly(I):poly(C). Nine to 12 mo after the treatment, the mRNAs for CCL-20 and G-CSF in the joints were quantified by real-time PCR and are expressed relative to the GAPDH mRNA level. Values are expressed relative to the GAPDH mRNA level, and the mean value is indicated by horizontal bars. *P* values are shown.



